association (references)

References for: association

Full identifier: http://purl.org/np/RAsJA-5zi6dJjp4usxaEBKAWNaMX5Gm4A0SaEJ2tXX3Bc#association

Nanopublication	Part	Subject	Predicate	Object	Published By	Published On
http://purl.org/np/RAsJA-5zi6... RAsJA-5zi6	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#object object	http://purl.obolibrary.org/obo/MONDO_0005414 MONDO_0005414	0000-0002-7641-6446	2021-08-24T16:18:41.079Z
http://purl.org/np/RAsJA-5zi6... RAsJA-5zi6	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject	https://identifiers.org/DRUGBANK:DB00363 DRUGBANK:DB00363	0000-0002-7641-6446	2021-08-24T16:18:41.079Z
http://purl.org/np/RAsJA-5zi6... RAsJA-5zi6	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	https://w3id.org/biolink/vocab/relation relation	https://w3id.org/um/neurodkg/OffLabelIndication OffLabelIndication	0000-0002-7641-6446	2021-08-24T16:18:41.079Z
http://purl.org/np/RAsJA-5zi6... RAsJA-5zi6	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#type type	http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement	0000-0002-7641-6446	2021-08-24T16:18:41.079Z
http://purl.org/np/RAsJA-5zi6... RAsJA-5zi6	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	https://w3id.org/biolink/vocab/provided_by provided_by	https://w3id.org/um/NeuroDKG NeuroDKG	0000-0002-7641-6446	2021-08-24T16:18:41.079Z
http://purl.org/np/RAsJA-5zi6... RAsJA-5zi6	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate	https://w3id.org/biolink/vocab/treats treats	0000-0002-7641-6446	2021-08-24T16:18:41.079Z
http://purl.org/np/RAsJA-5zi6... RAsJA-5zi6	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	https://w3id.org/biolink/vocab/has_population_context has_population_context	http://purl.org/np/RAsJA-5zi6...#context context	0000-0002-7641-6446	2021-08-24T16:18:41.079Z
http://purl.org/np/RAsJA-5zi6... RAsJA-5zi6	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	http://www.w3.org/2000/01/rdf-schema#label label	There are no FDA or manufacturer guidelines for use of clozapine in pediatric population. Clozapine has been used in the treatment of refractory schizophrenia in child and adolescents. It is estimated that 40%–50% of patients with very early-onset schizophrenia (VEOS) are nonresponders to first-line neuroleptics and that clozapine is likely to be beneficial.	0000-0002-7641-6446	2021-08-24T16:18:41.079Z
http://purl.org/np/RAsJA-5zi6... RAsJA-5zi6	links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion	association	https://w3id.org/biolink/vocab/publications publications	https://pubmed.ncbi.nlm.nih.gov/31082865 pubmed.ncbi.nlm.nih.gov/31082865	0000-0002-7641-6446	2021-08-24T16:18:41.079Z